The president and chief executive officer of the biotechnology company Opexa Therapeutics, Neil K. Warma, is slated to present two upcoming industry conferences in New York and Las Vegas. Opexa is responsible for the development of the novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), Tcelna, which is intended to become a personalized therapy specifically tailored to each patient’s disease profile.
In New York, the presentation will take place at the Rodman & Renshaw 16th Annual Healthcare Conference, on Tuesday, September 9, at 10:00 am EDT. The presentation will take place in the Kennedy II Salon in The New York Palace Hotel, or through the live webcast, which will be available on the company’s website until December 9, 2014.
On Friday, September 12th, Warma will be present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, from 9:45 am PDT, at The Encore at Wynn in Las Vegas, Nevada. The company will also provide a live webcast presentation on the Investor Relations section of their website. Mr. Warma has presented on Opexa’s therapy several times at conferences and international events in order to present developments on the company’s research and development of their lead product Tcelna.
With the purpose of creating a personalized treatment for multiple sclerosis, Opexa is currently conducting a phase IIb clinical development program to study its leading therapy candidate. Tcelna is a personalized T-cell immunotherapy for the treatment of Secondary Progressive MS. It is derived from T-cells isolated from a patient’s peripheral blood, expanded ex vivo, and reintroduced into the patient via subcutaneous injections, which triggers a potent immune response against specific subsets of autoreactive T-cells that attack myelin.
The phase IIb clinical trial, named Abili-T, is a randomized, double-blind, placebo-controlled clinical study in patients who demonstrate evidence of disease progression with or without associated relapses, which is being conducted at about 35 clinical sites in the U.S. and Canada with each patient being administrated with two annual courses of Tcelna treatment consisting of five subcutaneous injections per year. Opexa’s researchers are looking to measure the drug’s primary efficacy in percentage of brain volume change (atrophy) at 24 months, as well as disease progression, relapse rate and disability.